Feasibility Trial of Sodium-Glucose CoTransporter 2 INhibitors in Pediatric Chronic KIDney DiSease
EARLY_PHASE1
40
about 1.8 years
12–25
1 site in IL
What this study is about
Researchers are testing if it's possible to enroll children with chronic kidney disease into a clinical trial of empagliflozin. It will also explore whether taking empagliflozin for three months improves blood, urine, and heart function tests.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Empagliflozin 10 MG
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
empagliflozin (SGLT2 inhibitor; increases glucose excretion in urine)
Secondary: Serum N-terminal pro-brain natruetic peptide (NT-proBNP), Systolic Blood Pressure, Urine Albumin to Creatinine Ratio (UACr)
Renal